Connective tissue disease-associated interstitial lung disease : A focused review

Journal of Intensive Care Medicine

Volumn 30, Issue 7, 2015, Pages 392-400

  Solomon, Joshua J ^a   Fischer, Aryeh ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

acute exacerbation; connective tissue disease; interstitial lung disease; respiratory failure

Indexed keywords

CLINICAL EVALUATION; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG INDUCED DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG HEMORRHAGE; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; COMPLICATION; PROGNOSIS; RESPIRATORY INSUFFICIENCY;

CONNECTIVE TISSUE DISEASES; HUMANS; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; RESPIRATORY INSUFFICIENCY;

EID: 84941204238     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066613516579     Document Type: Review

References (90)

1. Raghu G, Collard HR, Egan JJ,. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183 (6): 788-824.
2. Lee HK, Kim DS, Yoo B,. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005; 127 (6): 2019-2027.
3. American Thoracic Society; European Respiratory Society. American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American thoracic society (ATS), and the European respiratory society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS executive committee, June 2001. Am J Respir Crit Care Med. 2002; 165 (2): 277-304.
4. Flaherty KR, Travis WD, Colby TV,. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. 2001; 164 (9): 1722-1727.
5. Flaherty KR, Toews GB, Travis WD,. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J. 2002; 19 (2): 275-283.
6. Bouros D, Wells AU, Nicholson AG,. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002; 165 (12): 1581-1586.
7. Park JH, Kim DS, Park IN,. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007; 175 (7): 705-711.
8. Kim EJ, Elicker BM, Maldonado F,. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010; 35 (6): 1322-1328.
9. Tsuchiya Y, Takayanagi N, Sugiura H,. Lung diseases directly associated with rheumatoid arthritis and their relation to outcome. Eur Respir J. 2011; 37 (6): 1411-1417.
10. Kim EJ, Collard HR, King TE Jr,. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009; 136 (5): 1397-1405.
11. Scott DL, Wolfe F, Huizinga TW,. Rheumatoid arthritis. Lancet. 2010; 376 (9746): 1094-1108.
12. Gabbay E, Tarala R, Will R,. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997; 156 (2 pt 1): 528-535.
13. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR,. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001; 56 (8): 622-627.
14. Saag KG, Kolluri S, Koehnke RK,. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996; 39 (10): 1711-1719.
15. Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI,. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol. 2008; 27 (4): 511-513.
16. Sakaida H,. IgG rheumatoid factor in rheumatoid arthritis with interstitial lung disease [in Japanese]. Ryumachi [Rheumatism]. 1995; 35 (4): 671-677.
17. Silva CI, Muller NL,. Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations. Semin Ultrasound CT MR. 2006; 27 (2): 111-116.
18. Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M,. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int. 2005; 25 (6): 429-435.
19. Shimizu Y, Sunaga N, Dobashi K,. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis. 2009; 9: 47.
20. Tanaka N, Kim JS, Newell JD,. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004; 232 (1): 81-91.
21. Leslie KO, Trahan S, Gruden J,. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med. 2007; 28 (4): 369-378.
22. Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS,. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest. 2009; 136 (1): 23-30.
23. Turesson C, Matteson EL, Colby TV,. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum. 2005; 52 (1): 73-79.
24. Devouassoux G, Cottin V, Liote H,. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J. 2009; 33 (5): 1053-1061.
25. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD,. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006; 116 (12): 3183-3194.
26. Gochuico BR, Avila NA, Chow CK,. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008; 168 (2): 159-166.
27. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med. 2009; 360 (19): 1989-2003.
28. Steen VD, Medsger TA,. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007; 66 (7): 940-944.
29. Schurawitzki H, Stiglbauer R, Graninger W,. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology. 1990; 176 (3): 755-759.
30. McNearney TA, Reveille JD, Fischbach M,. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum. 2007; 57 (2): 318-326.
31. Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA,. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest. 1998; 114 (3): 801-807.
32. Morelli S, Barbieri C, Sgreccia A,. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol. 1997; 24 (1): 81-85.
33. Goldin JG, Lynch DA, Strollo DC,. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008; 134 (2): 358-367.
34. Remy-Jardin M, Remy J, Wallaert B, Bataille D, Hatron PY,. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology. 1993; 188 (2): 499-506.
35. Ozbalkan Z, Topeli A, Kiraz S, Ozturk MA, Ertenli I, Calguneri M,. The contribution of underlying systemic rheumatic diseases to the mortality in patients admitted for intensive care: a matched cohort study. Clin Exp Rheumatol. 2004; 22 (2): 223-226.
36. Pourrat O, Bureau JM, Hira M, Martin Barbaz F, Descamps JM, Robert R,. Outcome of patients with systemic rheumatic diseases admitted to intensive care units: a retrospective study of 39 cases [in French]. Rev Med Interne. 2000; 21 (2): 147-151.
37. Takeishi M, Akiyama Y, Akiba H, Adachi D, Hirano M, Mimura T,. Leflunomide induced acute interstitial pneumonia. J Rheumatol. 2005; 32 (6): 1160-1163.
38. Quintero OL, Rojas-Villarraga A, Mantilla RD, Anaya JM,. Autoimmune diseases in the intensive care unit. an update. Autoimmun Rev. 2013; 12 (3): 380-395.
39. Gerbino AJ, Goss CH, Molitor JA,. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008; 133 (2): 455-460.
40. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI,. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010; 29 (10): 1167-1168.
41. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Laque R, Vilardell-Tarres M,. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol. 2011; 30 (11): 1393-1398.
42. Zamora AC, Wolters PJ, Collard HR,. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008; 102 (1): 150-155.
43. Liossis SN, Bounas A, Andonopoulos AP,. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006; 45 (8): 1005-1008.
44. Janssen NM, Karnad DR, Guntupalli KK,. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. Crit Care Clin. 2002; 18 (4): 729-748.
45. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G,. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004; 63 (3): 297-301.
46. Solomon J, Swigris JJ, Brown KK,. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011; 37 (1): 100-109.
47. Arakawa H, Yamada H, Kurihara Y,. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest. 2003; 123 (4): 1096-1103.
48. Mileti LM, Strek ME, Niewold TB, Curran JJ, Sweiss NJ,. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol. 2009; 15 (5): 254-255.
49. Koreeda Y, Higashimoto I, Yamamoto M,. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med. 2010; 49 (5): 361-369.
50. Fischer A, Swigris JJ, du Bois RM,. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009; 103 (11): 1719-1724.
51. Douglas WW, Tazelaar HD, Hartman TE,. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001; 164 (7): 1182-1185.
52. Marie I, Hachulla E, Cherin P,. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002; 47 (6): 614-622.
53. Suzuki Y, Hayakawa H, Miwa S,. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009; 187 (3): 201-206.
54. Ball EM, Savage EM, Pendleton A,. Refractory anti-synthetase syndrome treated with rituximab. Rheumatology (Oxford). 2010; 49 (5): 1013.
55. Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH,. Interstitial lung disease in primary Sjogren syndrome. Chest. 2006; 130 (5): 1489-1495.
56. Ito I, Nagai S, Kitaichi M,. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005; 171 (6): 632-638.
57. Swigris JJ, Fischer A, Gillis J, Meehan RT, Brown KK,. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest. 2008; 133 (1): 271-280.
58. Bertoli AM, Vila LM, Apte M,. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus. 2007; 16 (6): 410-417.
59. Bodolay E, Szekanecz Z, Devenyi K,. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford). 2005; 44 (5): 656-661.
60. Gunnarsson R, Aalokken TM, Molberg O,. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis. 2012; 71 (12): 1966-1972.
61. Saito Y, Terada M, Takada T,. Pulmonary involvement in mixed connective tissue disease: comparison with other collagen vascular diseases using high resolution CT. J Comput Assist Tomogr. 2002; 26 (3): 349-357.
62. Kozuka T, Johkoh T, Honda O,. Pulmonary involvement in mixed connective tissue disease: high-resolution CT findings in 41 patients. J Thorac Imaging. 2001; 16 (2): 94-98.
63. Lee J, Yim JJ, Yang SC,. Outcome of patients with connective tissue disease requiring intensive care for respiratory failure. Rheumatol Int. 2012; 32 (11): 3353-3358.
64. Thong BY, Tai DY, Goh SK, Johan A,. An audit of patients with rheumatic disease requiring medical intensive care. Ann Acad Med Singapore. 2001; 30 (3): 254-259.
65. Christ-Crain M, Jaccard-Stolz D, Bingisser R,. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004; 363 (9409): 600-607.
66. Christ-Crain M, Stolz D, Bingisser R,. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006; 174 (1): 84-93.
67. Stolz D, Stulz A, Muller B, Gratwohl A, Tamm M,. BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest. 2007; 132 (2): 504-514.
68. Maschmeyer G, Haas A, Cornely OA,. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007; 67 (11): 1567-1601.
69. Syrjala H, Broas M, Suramo I, Ojala A, Lahde S,. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis. 1998; 27 (2): 358-363.
70. Mori S, Sugimoto M,. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 (12): 2120-2130.
71. Wolfe F, Caplan L, Michaud K,. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006; 54 (2): 628-634.
72. Aoki Y, Iwamoto M, Kamata Y,. Prognostic indicators related to death in patients with pneumocystis pneumonia associated with collagen vascular diseases. Rheumatol Int. 2009; 29 (11): 1327-1330.
73. Kamata Y, Nara H, Kamimura T,. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med. 2004; 43 (12): 1201-1204.
74. Lateef O, Shakoor N, Balk RA,. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005; 4 (4): 723-730.
75. Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T,. Drug induced interstitial lung disease. Open Respir Med J. 2012; 6: 63-74.
76. Lara AR, Schwarz MI,. Diffuse alveolar hemorrhage. Chest. 2010; 137 (5): 1164-1171.
77. Santos-Ocampo AS, Mandell BF, Fessler BJ,. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest. 2000; 118 (4): 1083-1090.
78. Zamora MR, Warner ML, Tuder R, Schwarz MI,. Diffuse alveolar hemorrhage and systemic lupus erythematosus. clinical presentation, histology, survival, and outcome. Medicine. 1997; 76 (3): 192-202.
79. Hoshi K, Matsuda M, Ishikawa M,. Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus. Clin Rheum. 2004; 23 (3): 252-255.
80. Collard HR, Moore BB, Flaherty KR,. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007; 176 (7): 636-643.
81. Park IN, Kim DS, Shim TS,. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007; 132 (1): 214-220.
82. Suda T, Kaida Y, Nakamura Y,. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med. 2009; 103 (6): 846-853.
83. Papanikolaou IC, Drakopanagiotakis F, Polychronopoulos VS,. Acute exacerbations of interstitial lung diseases. Curr Opin Pulm Med. 2010; 16 (5): 480-486.
84. Parambil JG, Myers JL, Aubry MC, Ryu JH,. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. Chest. 2007; 132 (1): 50-57.
85. Parambil JG, Myers JL, Ryu JH,. Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases. Chest. 2006; 130 (2): 553-558.
86. Chen IJ, Jan Wu YJ, Lin CW,. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009; 28 (6): 639-646.
87. Silva CI, Muller NL,. Interstitial lung disease in the setting of collagen vascular disease. Semin Roentgenol. 2010; 45 (1): 22-28.
88. Ogawa D, Hashimoto H, Wada J,. Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford). 2000; 39 (12): 1422-1424.
89. Tanaka F, Origuchi T, Migita K,. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med. 2000; 39 (5): 428-430.
90. Clawson K, Oddis CV,. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum. 1995; 38 (10): 1519-1523.